These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1717551)

  • 1. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study.
    Naume B; Espevik T
    J Immunol; 1991 Oct; 147(7):2208-14. PubMed ID: 1717551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12.
    Naume B; Johnsen AC; Espevik T; Sundan A
    Eur J Immunol; 1993 Aug; 23(8):1831-8. PubMed ID: 7688307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells.
    Naume B; Shalaby R; Lesslauer W; Espevik T
    J Immunol; 1991 May; 146(9):3045-8. PubMed ID: 1707931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulatory signals are required for optimal proliferation of human natural killer cells.
    Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J
    J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
    Dadmarz R; Bockstoce DC; Golub SH
    Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lymphokine-activated killer cells by human pulmonary macrophages: discordance between up-regulation of the beta chain (p75) of the interleukin-2 receptor on CD56+ cells and limited response to interleukin-2.
    Yarbrough WC; Wilkes DS; Weissler JC
    Am J Respir Cell Mol Biol; 1994 Feb; 10(2):184-91. PubMed ID: 7509162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-alpha/beta secretion.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    J Immunol; 1993 Jun; 150(11):4844-55. PubMed ID: 8496590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.